All In Biotech

Drug Trial Radar · NCT03976401

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: Aug 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

May 28, 2019

Primary completion

Feb 10, 2021

Study completion Jan 10, 2022

Sponsor

Lead sponsor
Akero Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jun 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • EFXDrug

    Administered by subcutaneous injection

  • PlaceboDrug

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12.Time frame: 12 weeks

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Akero Clinical Study Site

    Tucson, Arizona

  • Akero Clinical Study Site

    Little Rock, Arkansas

  • Akero Clinical Study Site

    Huntington Park, California

  • Akero Clinical Study Site

    Los Angeles, California

  • Akero Clinical Study Site

    Los Angeles, California

  • Akero Clinical Study Site

    Panorama City, California

  • Akero Clinical Study Site

    Poway, California

  • Akero Clinical Study Site

    Boca Raton, Florida

  • Akero Clinical Study Site

    Lakewood Rch, Florida

  • Akero Clinical Study Site

    Miami, Florida

  • Akero Clinical Study Site

    New Port Richey, Florida

  • Akero Clinical Study Site

    Ocoee, Florida

  • Akero Clinical Study Site

    Port Orange, Florida

  • Akero Clinical Study Site

    Sarasota, Florida

  • Akero Clinical Study Site

    Baton Rouge, Louisiana

  • Akero Clinical Study Site

    Marrero, Louisiana

  • Akero Clinical Study Site

    Kansas City, Missouri

  • Akero Clinical Study Site

    Berlin, New Jersey

  • Akero Clinical Study Site

    Chattanooga, Tennessee

  • Akero Clinical Study Site

    Cedar Park, Texas

  • Akero Clinical Study Site

    Dallas, Texas

  • Akero Clinical Study Site

    Edinburg, Texas

  • Akero Clinical Study Site

    Fort Worth, Texas

  • Akero Clinical Study Site

    San Antonio, Texas

  • Akero Clinical Study Site

    San Antonio, Texas

  • Akero Clinical Study Site

    Webster, Texas

  • Akero Clinical Study Site

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.